Quick Answer
Indaptus Therapeutics, Inc. reported Earnings Per Share Diluted of $21.58 (loss) per share for the year ending 2025.
- Indaptus Therapeutics, Inc. showed an increase of +52.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Indaptus Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $0.46 (loss) per share | Q3 2022: $0.42 (loss) per share | Q1 2023: $0.51 (loss) per share | Q2 2023: $0.39 (loss) per share | Q3 2023: $0.47 (loss) per share | Q1 2024: $0.45 (loss) per share | Q2 2024: $13.16 (loss) per share | Q3 2024: $9.04 (loss) per share | Q1 2025: $0.32 (loss) per share | Q2 2025: $9.09 (loss) per share | Q3 2025: $2.98 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Indaptus Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 1,147.4%.
- Historical annual values: Fiscal year 2025: $21.58 (loss) per share | Fiscal year 2024: $44.96 (loss) per share | Fiscal year 2023: $1.83 (loss) per share | Fiscal year 2022: $1.73 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: